Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
- PMID: 33718107
- PMCID: PMC7947906
- DOI: 10.3389/fonc.2020.600573
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Abstract
Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient's own immune cells to kill tumors and revolutionizing cancer treatment in a variety of cancers. Although breast cancer was historically believed to be immunologically silent, treatment with immune checkpoint inhibitors has been shown to induce modest responses in metastatic breast cancer. Given the inherent heterogeneity of breast tumors, this raised the question whether certain breast tumors might benefit more from immune-based interventions and which cancer cell-intrinsic and/or microenvironmental factors define the likelihood of inducing a potent and durable anti-tumor immune response. In this review, we will focus on triple negative breast cancer as immunogenic breast cancer subtype, and specifically discuss the relevance of tumor mutational burden, the plethora and diversity of tumor infiltrating immune cells in addition to the immunoscore, the presence of immune checkpoint expression, and the microbiome in defining immune checkpoint blockade response. We will highlight the current immune checkpoint inhibitor treatment options, either as monotherapy or in combination with standard-of-care treatment modalities such as chemotherapy and targeted therapy. In addition, we will look into the potential of immunotherapy-based combination strategies using immune checkpoint inhibitors to enhance both innate and adaptive immune responses, or to establish a more immune favorable environment for cancer vaccines. Finally, the review will address the need for unambiguous predictive biomarkers as one of the main challenges of immune checkpoint blockade. To conclude, the potential of immune checkpoint blockade for triple negative breast cancer treatment could be enhanced by exploration of aforementioned factors and treatment strategies thereby providing promising future prospects.
Keywords: combination therapy; immune checkpoint blockade; predictive biomarkers; programmed death ligand-1 (PD-L1); programmed death-1 (PD-1); triple negative breast cancer; tumor infiltrating lymphocytes; tumor mutational burden.
Copyright © 2021 Thomas, Al-Khadairi and Decock.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.Jpn J Clin Oncol. 2021 Mar 3;51(3):321-332. doi: 10.1093/jjco/hyaa230. Jpn J Clin Oncol. 2021. PMID: 33324990 Review.
-
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4. Curr Treat Options Oncol. 2021. PMID: 33743085 Review.
-
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933. Clin Adv Hematol Oncol. 2016. PMID: 27930644 Review.
-
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879. JAMA Netw Open. 2019. PMID: 31290993 Free PMC article.
-
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.Expert Opin Investig Drugs. 2022 Jun;31(6):567-591. doi: 10.1080/13543784.2022.2049232. Epub 2022 Mar 9. Expert Opin Investig Drugs. 2022. PMID: 35240902 Review.
Cited by
-
Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.J Immunother Cancer. 2021 Jun;9(6):e002036. doi: 10.1136/jitc-2020-002036. J Immunother Cancer. 2021. PMID: 34083415 Free PMC article.
-
Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.Med Oncol. 2022 Dec 15;40(1):48. doi: 10.1007/s12032-022-01922-6. Med Oncol. 2022. PMID: 36520261 Free PMC article. Review.
-
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.Front Oncol. 2022 Jun 20;12:919072. doi: 10.3389/fonc.2022.919072. eCollection 2022. Front Oncol. 2022. PMID: 35795050 Free PMC article. Review.
-
O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.Front Immunol. 2022 Jan 3;12:791551. doi: 10.3389/fimmu.2021.791551. eCollection 2021. Front Immunol. 2022. PMID: 35046949 Free PMC article.
-
Biology-aware mutation-based deep learning for outcome prediction of cancer immunotherapy with immune checkpoint inhibitors.NPJ Precis Oncol. 2023 Nov 6;7(1):117. doi: 10.1038/s41698-023-00468-8. NPJ Precis Oncol. 2023. PMID: 37932419 Free PMC article.
References
-
- Ferlay J, Ervik J, Lam F, Colombet M, Mery L, Piñeros M, et al. . Global Cancer Observatory: Cancer Today. Lyon Fr Int Agency Res Cancer (2018). 10.1051/0004-6361/201016331 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials